Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Slides:

Advertisements

Similar presentations

Volume 61, Issue 5, Pages (May 2012)

Advertisements

Volume 68, Issue 6, Pages (December 2015)

Volume 155, Issue 3, Pages (March 1996)

The PSA Era is not Over for Prostate Cancer

Volume 69, Issue 3, Pages (March 2016)

Volume 58, Issue 2, Pages (August 2010)

Volume 44, Issue 6, Pages (December 2003)

Volume 58, Issue 4, Pages (October 2010)

Volume 58, Issue 5, Pages (November 2010)

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer: Highlights from 2006

European Urology Oncology

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.

Volume 70, Issue 2, Pages (August 2016)

Volume 72, Issue 5, Pages (November 2017)

Volume 52, Issue 4, Pages (October 2007)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 54, Issue 4, Pages (October 2008)

Volume 53, Issue 4, Pages (April 2008)

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Volume 67, Issue 3, Pages (March 2015)

Volume 199, Issue 4, Pages e768-e769 (April 2018)

Volume 64, Issue 5, Pages (November 2013)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 69, Issue 6, Pages (June 2016)

Volume 71, Issue 5, Pages (May 2017)

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 53, Issue 4, Pages (April 2008)

Luis Martínez-Piñeiro European Urology Supplements

Volume 73, Issue 2, Pages (February 2018)

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 5, Pages (May 2012)

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

11C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate Cancer I.J de Jong, J Pruim, P.H Elsinga, W Vaalburg,

Volume 53, Issue 4, Pages (April 2008)

Volume 61, Issue 2, Pages (February 2012)

Volume 66, Issue 2, Pages (August 2014)

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Volume 74, Issue 2, Pages (August 2018)

Volume 62, Issue 6, Pages (December 2012)

Volume 70, Issue 2, Pages (August 2016)

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography Andrew.

Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective,

The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer

Volume 71, Issue 5, Pages (May 2017)

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Long-Term Hormonal Therapy: Who Would Benefit?

Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer Felix Preisser, Michele Marchioni, Sebastiano.

European Urology Oncology

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study Andrew M. Erickson, Stefano Luzzago, Axel.

Volume 74, Issue 6, Pages (December 2018)

European Urology Oncology

European Urology Oncology

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Fernando P. Secin, Fernando J. Bianco, Nicholas T

Volume 52, Issue 1, Pages (July 2007)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Axel Heidenreich European Urology Supplements

European Urology Oncology

Volume 51, Issue 5, Pages (May 2007)

Salvage Local Treatments After Focal Therapy for Prostate Cancer

European Urology Oncology

Presentation transcript:

Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G. Nguyen, Katsuto Shinohara, Matthew R. Cooperberg, Peter R. Carroll European Urology Oncology Volume 1, Issue 5, Pages 386-394 (October 2018) DOI: 10.1016/j.euo.2018.04.018 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 CONSORT diagram of patient selection within the prospective study of active surveillance at University of California San Francisco. European Urology Oncology 2018 1, 386-394DOI: (10.1016/j.euo.2018.04.018) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier curves for reclassification-free survival by Gleason grade 3+3 (n=1119) and 3+4 (n=124) at diagnostic biopsy for the active surveillance cohort at University of California San Francisco. European Urology Oncology 2018 1, 386-394DOI: (10.1016/j.euo.2018.04.018) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier curves for treatment-free survival by Gleason grade 3+3 (n=1119) and 3+4 (n=124) at diagnostic biopsy for the active surveillance cohort at University of California San Francisco. European Urology Oncology 2018 1, 386-394DOI: (10.1016/j.euo.2018.04.018) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 4 Kaplan-Meier curves for treatment-free survival by Gleason grade at diagnostic biopsy and upgrade during surveillance for the active surveillance cohort at University of California San Francisco. European Urology Oncology 2018 1, 386-394DOI: (10.1016/j.euo.2018.04.018) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 5 Kaplan-Meier curves for biochemical recurrence-free survival after deferred radical prostatectomy by Gleason grade 3+3 (n=223 of 325) and 3+4 (n=24 of 42) at diagnostic biopsy for the active surveillance cohort at University of California San Francisco. Patients had two or more postoperative prostate-specific antigen values. European Urology Oncology 2018 1, 386-394DOI: (10.1016/j.euo.2018.04.018) Copyright © 2018 European Association of Urology Terms and Conditions